Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3

Benzinga · 01/06/2023 10:24
Jefferies analyst Michael Yee upgrades Aligos Therapeutics (NASDAQ:ALGS) from Hold to Buy and raises the price target from $2.5 to $3.